Merck & Daiichi Sankyo Report the P-II (IDeate-Lung01) Study Data of Ifinatamab Deruxtecan to Treat Extensive-Stage Small Cell Lung Cancer
Shots:
- The P-II (IDeate-Lung01) study is assessing ifinatamab deruxtecan in ES-SCLC patients previously treated with 1-3L of therapies, to receive 8mg/kg or 12mg/kg (part 1), & at least 2L of therapy, to receive the recommended 12mg/kg (part 2)
- Results showed cORR: 54.8% with 23 PRs (12mg/kg) & 26.1% with 1 CR and 11 PRs (8mg/kg), mDoR: 4.2mos. & 7.9mos., DCR: 90.5% & 80.4%, mPFS: 5.5mos. & 4.2mos. and mOS: 11.8mos. & 9.4mos. The 12mg/kg dose is selected for the expansion phase
- In patients with brain target lesions intracranial ORRs were 50.0% with 3 PRs (12mg/kg, n=10) & 66.7% with 2 PRs (8mg/kg, n=6), 2 CRs were found in each cohort. Stable disease was observed in 5 (12mg/kg) & 2 cases (8mg/kg)
Ref: Merck | Image: Merck & Daiichi Sankyo
Related News:- Merck and Daiichi Sankyo Report the Initiation of P-III (IDeate-Lung02) Study of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
